Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

[1]  C. Perou,et al.  c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer , 2014, Oncogene.

[2]  H. Ikeda,et al.  Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. , 2014, Human pathology.

[3]  X. An,et al.  MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy , 2014, Cancer.

[4]  Z. Qian,et al.  HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma , 2014, British Journal of Cancer.

[5]  S. Ou,et al.  Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. , 2013, Discovery medicine.

[6]  J. Ji,et al.  FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547 , 2013, Clinical Cancer Research.

[7]  W. Kim,et al.  Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. , 2012, Human pathology.

[8]  Y. Kodera,et al.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry , 2012, Gastric Cancer.

[9]  H. Lee,et al.  MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome , 2012, British Journal of Cancer.

[10]  J. Inazawa,et al.  Gene amplification of ESR1 in breast cancers—fact or fiction? A fluorescence in situ hybridization and multiplex ligation‐dependent probe amplification study , 2012, The Journal of pathology.

[11]  J. Bartlett,et al.  HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.

[12]  Khay Guan Yeoh,et al.  A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets , 2012, Gut.

[13]  K. Matsumoto,et al.  FGFR2 gene amplification and clinicopathological features in gastric cancer , 2012, British Journal of Cancer.

[14]  Jeffrey W. Clark,et al.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Peter A Kaufman,et al.  C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[17]  D. Berney,et al.  The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. , 2010, The American journal of pathology.

[18]  P. V. van Diest,et al.  Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[19]  O. Myklebost,et al.  Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3A , 2007, International journal of cancer.

[20]  J. Inazawa,et al.  Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas , 2007, Modern Pathology.

[21]  B. Spencer‐Dene,et al.  Stomach development is dependent on fibroblast growth factor 10/fibroblast growth factor receptor 2b-mediated signaling. , 2006, Gastroenterology.

[22]  C. Cremers,et al.  Mutations in different components of FGF signaling in LADD syndrome , 2006, Nature Genetics.

[23]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Lane,et al.  Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. , 2004, Chemistry & biology.

[25]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[26]  H. Fujii,et al.  Expression of epidermal growth factor receptor in gastric carcinomas. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  D. Larsimont,et al.  HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  K. Yanagihara,et al.  Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[29]  Tanaki Kajitani,et al.  The general rules for the gastric cancer study in surgery and pathology , 1981, The Japanese journal of surgery.

[30]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[31]  D. Sir.  Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: New insights in optimal cut-off value ∗ , 2010 .

[32]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[33]  Y. Oda,et al.  Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.

[34]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[35]  T. Nagayo.  Tumours of the stomach. , 1973, IARC scientific publications.